炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会!(来源:上观新闻)从药物获批新适应症到临床研究取得新进展,浦东生物医药企业成果不断。日前,和黄医药的1类新药索乐匹尼布片拟纳入优先审评;翰森制药阿美乐第五项适应症“靶化联合”获批上市;易慕峰生物在国际研讨会上公布在研新型细胞治疗产品取得突破进展。作为上海生物医药产业发展的主要承载区,浦东持续集聚各方力量和资源,打造覆盖基础研究...
Source Link炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会!(来源:上观新闻)从药物获批新适应症到临床研究取得新进展,浦东生物医药企业成果不断。日前,和黄医药的1类新药索乐匹尼布片拟纳入优先审评;翰森制药阿美乐第五项适应症“靶化联合”获批上市;易慕峰生物在国际研讨会上公布在研新型细胞治疗产品取得突破进展。作为上海生物医药产业发展的主要承载区,浦东持续集聚各方力量和资源,打造覆盖基础研究...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.